drugset
Drugs / VERPASEP CALTESPEN
last change Jun 2008 re-read 2 minutes ago

VERPASEP CALTESPEN

also known as HspE7 · SGN-00101 · BCG-65-E7 · Verpasep caltespeno

Vaccine

Developed for
cervical cancer · cervical intraepithelial neoplasia grade 2/3 · anal carcinoma · cervical intraepithelial neoplasia · cervical squamous intraepithelial neoplasia · papilloma · precancerous condition · recurrent respiratory papillomatosis
+1 more · dysplasia of cervix
Investigated by
National Cancer Institute (NCI) · Nventa Biopharmaceuticals Corporation · Dana-Farber/Brigham and Women's Cancer Center

Trials 6 · a red edge is where a trial was stopped

today NCT00493545 · Ph 1 NCT00091130 · Ph 2 NCT00054041 · Ph 2 NCT00060099 · Ph 2 NCT00052897 · Ph 1/2 NCT00038714 · Ph 2
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT00493545 May 2007 → Jun 2008 cervical intraepithelial neoplasia Nventa Biopharmaceuticals Corporation Unknown No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT00052897 Dec 2002 → Jul 2005 anal carcinoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 24 trials
Phase 2 NCT00091130 Sep 2004 → Jun 2007 cervical cancer, cervical intraepithelial neoplasia grade 2/3, cervical squamous intraepithelial neoplasia National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT00054041 Jun 2004 → Jan 2007 cervical cancer, cervical intraepithelial neoplasia grade 2/3, human papilloma virus infection National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT00060099 May 2003 → ? precancerous condition Dana-Farber/Brigham and Women's Cancer Center Unknown No outcome recorded
Phase 2 NCT00038714 Nov 2001 → Jan 2004 papilloma, recurrent respiratory papillomatosis Nventa Biopharmaceuticals Corporation Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00075569 Comparator Mar 2004 → Aug 2005 cervical cancer, dysplasia of cervix Albert Einstein College of Medicine Completed No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as VERPASEP CALTESPEN ChEMBL registry synonym — accepted as the source's own label CHEMBL2108664 ↗
Known as BCG-65-E7 ChEMBL registry synonym — accepted as the source's own label CHEMBL2108664 ↗
Known as HspE7 “Phase II Randomized, Double-Blinded Trial Of SGN-00101 (HSP-E7) For Treatment Of CIN II/III” NCT00060099 ↗
5

NCT00075569 ↗

NCT00091130 ↗

NCT00052897 ↗

NCT00493545 ↗

NCT00054041 ↗
Known as SGN-00101 “Phase II Randomized, Double-Blinded Trial Of SGN-00101 (HSP-E7) For Treatment Of CIN II/III” NCT00060099 ↗
1

NCT00038714 ↗
Known as Verpasep caltespeno ChEMBL registry synonym — accepted as the source's own label CHEMBL2108664 ↗
Modality Vaccine “SGN-00101 (HspE7, Nventa, San Diego, CA) is a novel therapeutic vaccine consisting of a fusion protein containing an M. bovis BCG heat shock protein (Hsp65) covalently linked...” NCT00075569 ↗
Route Subcutaneous “Each patient underwent 3 monthly subcutaneous vaccinations with 500 microg of HspE7” PMID 17586030 ↗ Jun 2007